Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TP53 | P04637 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22424906 | 0.89 | RAB9A (0.57) | NPC1RAB9AKMT2AMEN1SMYD3 | |
| SCHEMBL22425108 | 0.84 | GRM5 (0.55) | NPC1RAB9AKMT2AMEN1SMYD3 | |
| SCHEMBL22425176 | 0.84 | MEN1 (0.59) | NPC1RAB9AKMT2AMEN1SMYD3 | |
| SCHEMBL22424922 | 0.84 | RAB9A (0.59) | NPC1RAB9AKMT2AMEN1SMYD3 | |
| SCHEMBL22425050 | 0.83 | RAB9A (0.61) | NPC1RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL22425056 | 0.82 | GRIN2D (0.56) | NPC1RAB9AKMT2AMEN1SMYD3 | |
| SCHEMBL3574898 | 0.81 | SMYD3 (0.49) | SMYD3EPHX2 | |
| SCHEMBL154971 | 0.81 | SMYD3 (0.60) | SMYD3KIF11TLK2 | |
| SCHEMBL22425052 | 0.81 | NPC1 (0.57) | NPC1RAB9AKMT2AMEN1SMYD3 | |
| SCHEMBL22424887 | 0.80 | SMYD3 (0.56) | SMYD3KIF11GAATLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230366033-A1 | METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230366033-A1 | METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-16 | — | — | US | disclosed |
| US-20220151991-A1 | SMALL MOLECULE GRB2 STABILIZERS FOR RAS MAP KINASE INHIBITION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-19 | — | — | US | disclosed |
| WO-2020186202-A1 | SMALL MOLECULE GRB2 STABILIZERS FOR RAS MAP KINASE INHIBITION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151991-A1 | SMALL MOLECULE GRB2 STABILIZERS FOR RAS MAP KINASE INHIBITION | GRB2, KRAS, HRAS | NPC1 3236/4885RAB9A 348/4885KMT2A 2941/4885 |
| US-20230366033-A1 | METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR | GRB2, RAD51, MRE11 | NPC1 4337/4885RAB9A 1780/4885KMT2A 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.